Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Live Reaction from the American College of Cardiology Conference: A discussion with an ACC attendee on the the latest PCSK9 data from FOURIER and ORION-1.

Ticker(s): AMGN, SNY, REGN, MDCO, ALNY

Who's the expert?

Name: Dr Nihar Desai - MD

Institution: Yale School of Medicine

Bio: 

  • Professor of Cardiovascular Medicine and an Investigator in the Center for Outcomes Research and Evaluation
  • Treats 300 patients/month at both inpatient and outpatient settings (60 on Repatha)
  • Will be attending the ACC Conference and the AMGN presentation Friday morning.
  • His interests focus on comparative effectiveness of antiplatelet and antithrombotic therapy, identifying opportunities to improve outcomes, and evaluating the impact of novel care delivery systems on cost and quality.

Interview Questions
Q1.

Can you describe your background and experience treating patients with high levels of LDL cholesterol at risk of cardiovascular disease? How many patients do you see and what is your typical course of treatment? 

Added By: pjloria
Q2.

How safe and effective are current treatment options? Specifically statin therapy and dieting. Please elaborate on any other methods used. 

Added By: pjloria
Q3.

How do these current methods compare to what you have seen in the data so far for Repatha and Praluent? In terms of safety and efficacy?

Added By: pjloria
Q4.

What are your high level thoughts on the FOURIER study results? Do you think this will drive meaningful change in the prescribing of Repatha? 

Added By: pjloria
Q5.

What should we be looking for in the EBBINGHAUS study details that will be presented on March 18th? 

Added By: pjloria
Q6.

Did the FOURIER results meet your expectations on what was a clinically meaningful benefit?

Added By: pjloria
Q7.

What percentage of the patient population do you see as a fit for taking Repatha? 

Added By: pjloria
Q8.

Depending on data: Do you think these FOURIER results for Repatha will impact the PCKS9 class positively? Will Repatha take share from Praluent or will the overall class grow?

Added By: pjloria
Q9.

The Medicines Company reported positive Top-Line results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran. What are your early thoughts on this data? How important is dose frequency in this patient population?

Added By: joe_mccann
Q10.

What was the energy/reaction of the physicians at the presentation?

Added By: joe_mccann
Q11.

How does today's result influence your view of Praluent's ODYSSEY OUTCOMES trial? Does the longer duration of that trial potentially help the results in light of Amgen's exploratory analysis of outcomes after a year?

Added By: joe_mccann
Q12.

What do you make of this comment by Sean E. Harper, M.D., executive vice president of Research and Development at Amgen:
"There is no legitimate criticism you can make about the efficacy outcome, though you do have to be able to interpret the data"?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.